JAC Advance Access originally published online on March 14, 2007
Journal of Antimicrobial Chemotherapy 2007 59(5):866-873; doi:10.1093/jac/dkm054
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong
1 Department of Microbiology, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China 2 Tuberculosis Reference Laboratory, Public Health Laboratory Centre, Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region, Kowloon, Hong Kong, China
Received 22 November 2006; returned 8 January 2007; revised 1 February 2007; accepted 3 February 2007
* Corresponding author. Tel: +852-2632-3339; Fax: +852-2647-3227; E-mail: chiuychan{at}cuhk.edu.hk
Objectives: To characterize 250 drug-resistant Mycobacterium tuberculosis (MTB) isolates in Hong Kong with respect to their drug susceptibility phenotypes to five common anti-tuberculosis drugs (ofloxacin, rifampicin, ethambutol, isoniazid and pyrazinamide) and the relationship between such phenotypes and the patterns of genetic mutations in the corresponding resistance genes (gyrA, rpoB, embB, katG, inhA, ahpC and pncA).
Methods: The MIC values of the aforementioned anti-tuberculosis drugs were determined for each of the 250 drug-resistant MTB clinical isolates by the absolute concentration method. Genetic mutations in the corresponding resistance genes in these MTB isolates were identified by PCR-single-stranded conformation polymorphism/multiplex PCR amplimer conformation analysis (SSCP/MPAC), followed by DNA sequencing of the purified PCR products.
Results: Resistance to four or five drugs was commonly observed in these MTB isolates; such phenotypes accounted for over 34% of the 250 isolates. The most frequently observed phenotypes were those involving both rifampicin and isoniazid, with or without additional resistance to the other drugs. A total of 102 novel mutations, which accounted for 80% of all mutation types detected in the 7 resistance genes, were recovered. Correlation between phenotypic and mutational data showed that genetic changes in the gyrA, rpoB and katG genes were more consistently associated with a significant resistance phenotype. Despite this, however, a considerable proportion of resistant MTB isolates were found to harbour no detectable mutations in the corresponding gene loci.
Conclusions: These findings expand the spectrum of potential resistance-related mutations in MTB clinical isolates and help consolidate the framework for the development of molecular methods for delineating the drug susceptibility profiles of MTB isolates in clinical laboratories.
Keywords: MPAC , MDR-TB , tuberculosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. T. Evans, A. Parveen, G. E. Smith, L. Xu, E. W. C. Chan, R. C. Y. Chan, and P. M. Hawkey Application of denaturing HPLC to rapidly identify rifampicin-resistant Mycobacterium tuberculosis in low- and high-prevalence areas J. Antimicrob. Chemother., February 1, 2009; 63(2): 295 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Mokrousov, T. Otten, O. Manicheva, Y. Potapova, B. Vishnevsky, O. Narvskaya, and N. Rastogi Molecular Characterization of Ofloxacin-Resistant Mycobacterium tuberculosis Strains from Russia Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2937 - 2939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Safi, B. Sayers, M. H. Hazbon, and D. Alland Transfer of embB Codon 306 Mutations into Clinical Mycobacterium tuberculosis Strains Alters Susceptibility to Ethambutol, Isoniazid, and Rifampin Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2027 - 2034. [Abstract] [Full Text] [PDF]
|
|